PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.25%
Revenue growth under 50% of META's 12.29%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.22%
Gross profit growth under 50% of META's 12.33%. Michael Burry would be concerned about a severe competitive disadvantage.
-0.53%
Negative EBIT growth while META is at 10.27%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-0.53%
Negative operating income growth while META is at 16.44%. Joel Greenblatt would press for urgent turnaround measures.
4.36%
Net income growth under 50% of META's 10.17%. Michael Burry would suspect the firm is falling well behind a key competitor.
9.09%
EPS growth at 75-90% of META's 10.47%. Bill Ackman would push for improved profitability or share repurchases to catch up.
9.09%
Diluted EPS growth at 75-90% of META's 11.04%. Bill Ackman would expect further improvements in net income or share count reduction.
0.21%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.41%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-28.47%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-26.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
4779.75%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
582.01%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
114.77%
3Y revenue/share CAGR 1.25-1.5x META's 77.04%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
753.63%
5Y OCF/share CAGR 1.25-1.5x META's 653.02%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
82.83%
3Y OCF/share CAGR at 50-75% of META's 125.05%. Martin Whitman would suspect weaker recent execution or product competitiveness.
5997.27%
Net income/share CAGR above 1.5x META's 2770.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
1524.07%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
96.69%
Below 50% of META's 194.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
2586.26%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
125.91%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.98%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
32.44%
Inventory growth of 32.44% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
4.91%
Similar asset growth to META's 5.19%. Walter Schloss finds parallel expansions or investment rates.
5.63%
Similar to META's 5.80%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
10.28%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-5.54%
We cut SG&A while META invests at 12.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.